Acceder

Publicaciones - HEMATOLOGÍA Y ONCOLOGÍA MÉDICA CLÍNICO-EXPERIMENTAL

Cargando...
Guerrero C, Larrayoz MJ, Erdozain I, Puig N, Cedena MT, Maia C, Manu A, Gordillo N, Churruca O, Alignani D, Sarvide S, Vazquez I, Perez C, Oriol A, Rosinol L, Rios-Tamayo R, Gonzalez-Perez MS, Gonzalez-Rodriguez AP, de Arriba F, Moraleda JM, Martin J, Palomera L, Cabanas V, Calasanz MJ, Martinez-Lopez J, Mateos MV, Blade J, Lahuerta JJ, San-Miguel JF, Paiva B. Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma. Blood Cancer Discov. 2025 May 5;6(3):203-216. doi: 10.1158/2643-3230.BCD-24-0274. PubMed PMID: 40232156; PubMed Central PMCID: PMC12050965.
AÑO: 2025; IF: 11.5
40232156
Cedena MT, Puig N, Paiva B, de la Puerta Rueda JE, Perez-Montana A, Casanova M, Brena Atienza J, Garcia A, de Arriba F, Martinez-Chamorro C, Sirvent M, Blanchard MJ, Alonso Fernandez R, Alvarez Rivas MA, Capote FJ, Garcia-Sanchez R, Perez JJ Sr, Rodriguez-Otero P, Lahuerta JJ, Martinez-Lopez J, Mateos MV, San-Miguel JF. Real-world evidence of measurable residual disease assessment in multiple myeloma. Blood Adv. 2025 Dec 11:bloodadvances.2025018454. doi: 10.1182/bloodadvances.2025018454. Online ahead of print. No abstract available. PubMed PMID: 41380099.
AÑO: 2025; IF: 7.1
41380099
Coucelo M, Sargas C, Ayala R, Larrayoz MJ, Chillon MC, Soria E, Bilbao C, de la Torre EP, Amorim ML, Mirales A, Cionfrini A, Simoes AT, Oliveira AC, Rodriguez-Veiga R, Lloret-Madrid P, Mendizabal Y, Botella C, Bernal T, Bergua J, Algarra L, Tormo M, Sarmento-Ribeiro AB, Trigo F, Cortesao E, Martinez-Sanchez P, Serrano J, Alonso-Dominguez JM, Garcia R, Amigo ML, Herrera-Puente P, Sayas MJ, Abuin A, Martinez-Lopez J, Calasanz MJ, Garcia-Sanz R, Gutierrez N, Perez-Simon JA, Gomez Casares MT, Sanchez-Garcia J, Montesinos P, Barragan E; PETHEMA group. Interlaboratory cross validation of acute myeloid leukemia fusion genes and mutational targets detected by PCR: Performance of PETHEMA central laboratories. Leuk Res. 2025 Dec 19;160:108149. doi: 10.1016/j.leukres.2025.108149. Online ahead of print. PubMed PMID: 41443144.
AÑO: 2025; IF: 2.2
41443144
Jimenez-Fonseca P, Alvarez-Escola C, Ballester Navarro I, Hernando Cubero J, Gonzalez Fernandez L, Mangas Cruz MA, Iglesias C, Garcia-Donas J, Picon MJ, Paja M, Gonzalez Batanero L, Garcia L, Molina J, Jimeno Mate R, Aller J, Romero MDCT, Cardenas Salas J, Gutierrez-Buey G, Egana Zunzunegui N, Navarro M, Lecumberri MJ, Valdes N, Carmona-Bayonas A. External validation of the S-GRAS score for predicting recurrence in patients with adrenocortical carcinoma: implications for adjuvant mitotane therapy. Eur J Endocrinol. 2025 Jul 31;193(2):320-328. doi: 10.1093/ejendo/lvaf171. PubMed PMID: 40810251.
AÑO: 2025; IF: 5.2
40810251
Capdevila J, Tafuto S, Krogh M, Teule A, Garcia-Carbonero R, Klumpen HJ, Cremer B, Sevilla I, Eriksson B, Tabaksblat E, Metges JP, Reed NS, Schrader J, Navarro V, Valenti V, Hernando J, Colao AM, Vestermark L, Carnaghi C, Knigge UP, Jimenez-Fonseca P, Benavent M, de Vos-Geelen J, Venerito M, Von Werder A, Jann H, Rinke A, Smith D, Horsch D, Starling N, Ruszniewski P, Baudin E, Caroli-Bosc FX, Manzano JL, Martin M, Scarpa A, Lawlor RT, Ragulan C, Ps H, Sadanandam A, Carmona-Bayonas A, Salazar R. Streptozotocin plus 5-fluorouracil followed by everolimus or the reverse sequence in patients with advanced pancreatic neuroendocrine tumors (SEQTOR-GETNE phase III study): a randomized clinical trial. ESMO Open. 2025 Dec;10(12):105922. doi: 10.1016/j.esmoop.2025.105922. Epub 2025 Dec 2. PubMed PMID: 41337860; PubMed Central PMCID: PMC12720089.
AÑO: 2025; IF: 8.3
41337860
< AnteriorSiguiente >
IMIB-Arrixaca

Instituto de Investigación Sanitaria Acreditado

ISCII

HEMATOLOGÍA Y ONCOLOGÍA MÉDICA CLÍNICO-EXPERIMENTAL